La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Meridian Bioscience Gestion
Gestion contrôle des critères 3/4
Meridian Bioscience's CEO is Jack Kenny, appointed in Oct 2017, has a tenure of 5.33 years. total yearly compensation is $4.60M, comprised of 15.4% salary and 84.6% bonuses, including company stock and options. directly owns 0.28% of the company’s shares, worth $4.17M. The average tenure of the management team and the board of directors is 3.6 years and 6.8 years respectively.
Informations clés
Jack Kenny
Directeur général
US$4.6m
Rémunération totale
| Pourcentage du salaire du PDG | 15.4% |
| Durée du mandat du directeur général | 5.3yrs |
| Propriété du PDG | 0.3% |
| Durée moyenne d'occupation des postes de direction | 3.6yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 6.8yrs |
Mises à jour récentes de la gestion
Recent updates
Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M
Aug 05Meridian Bioscience: High-Probability Merger Arbitrage
Jul 26Meridian Bioscience downgraded at William Blair on $1.53B acquisition
Jul 07Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet
Jun 27
Meridian Bioscience: Correctly Valued
Jun 26Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital
Jun 09Meridian Bioscience: Deceptively Priced
Mar 14Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns
Feb 03These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely
Jul 19If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy
Jul 08Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine
May 10Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation
May 08Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly
Mar 31Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?
Mar 11Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%
Feb 24Need To Know: Analysts Are Much More Bullish On Meridian Bioscience, Inc. (NASDAQ:VIVO) Revenues
Feb 09
Meridian expands production capacity for COVID-19 tests with NIH funding
Feb 03Should We Be Excited About The Trends Of Returns At Meridian Bioscience (NASDAQ:VIVO)?
Jan 27Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Sep 30 2022 | US$5m | US$710k | US$42m |
| Jun 30 2022 | n/a | n/a | US$43m |
| Mar 31 2022 | n/a | n/a | US$62m |
| Dec 31 2021 | n/a | n/a | US$60m |
| Sep 30 2021 | US$3m | US$690k | US$71m |
| Jun 30 2021 | n/a | n/a | US$71m |
| Mar 31 2021 | n/a | n/a | US$87m |
| Dec 31 2020 | n/a | n/a | US$70m |
| Sep 30 2020 | US$3m | US$670k | US$46m |
| Jun 30 2020 | n/a | n/a | US$44m |
| Mar 31 2020 | n/a | n/a | US$21m |
| Dec 31 2019 | n/a | n/a | US$19m |
| Sep 30 2019 | US$1m | US$650k | US$24m |
| Jun 30 2019 | n/a | n/a | US$26m |
| Mar 31 2019 | n/a | n/a | US$27m |
| Dec 31 2018 | n/a | n/a | US$26m |
| Sep 30 2018 | US$2m | US$542k | US$24m |
Rémunération vs marché: Jack's total compensation ($USD4.60M) is about average for companies of similar size in the US market ($USD5.11M).
Rémunération et revenus: Jack's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
PDG
Jack Kenny (53 yo)
5.3yrs
Titularisation
US$4,598,825
Compensation
Mr. John P. Kenny, also known as Jack, has been the Chief Executive Officer of Meridian Bioscience, Inc. since October 9, 2017. Mr. Kenny serves as President of Meridian Bioscience, Inc. and served as its...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 5.3yrs | US$4.60m | 0.28% $ 4.2m | |
| Executive VP & CFO | less than a year | US$1.03m | 0.0092% $ 137.4k | |
| Senior VP | 1.2yrs | US$786.42k | 0.097% $ 1.5m | |
| Executive Vice President of Life Science Business Unit | 9.4yrs | US$1.23m | 0.13% $ 2.0m | |
| Executive Vice President of Diagnostics | 2.8yrs | US$1.20m | 0.038% $ 567.0k | |
| Director of Corporate Finance | no data | pas de données | pas de données | |
| Vice President of Corporate Strategy | 3.1yrs | pas de données | pas de données | |
| Senior VP & General Counsel | less than a year | pas de données | pas de données | |
| Vice President of Global Human Resources | 4.8yrs | pas de données | pas de données | |
| Consultant | 4.3yrs | US$626.75k | pas de données | |
| Consultant | 4.1yrs | US$432.97k | pas de données |
3.6yrs
Durée moyenne de l'emploi
57yo
Âge moyen
Gestion expérimentée: VIVO's management team is considered experienced (3.6 years average tenure).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| President | 6.1yrs | US$4.60m | 0.28% $ 4.2m | |
| Independent Director | 5.5yrs | US$176.25k | 0.056% $ 833.6k | |
| Chairman | 7.5yrs | US$212.75k | 0.043% $ 638.2k | |
| Independent Director | 13.6yrs | US$197.00k | 0.069% $ 1.0m | |
| Independent Director | 4.4yrs | US$192.50k | 0.017% $ 247.7k | |
| Independent Director | 2.6yrs | US$189.63k | 0.028% $ 422.8k | |
| Independent Director | 8.6yrs | US$177.50k | 0.033% $ 487.1k | |
| Independent Director | 7.5yrs | US$191.13k | 0.031% $ 457.5k |
6.8yrs
Durée moyenne de l'emploi
66yo
Âge moyen
Conseil d'administration expérimenté: VIVO's board of directors are considered experienced (6.8 years average tenure).